Steven Nisticò,1,2 Mario Sannino,1 Ester Del Duca,1 Federica Tamburi,3 Ugo Bottoni2 and Giovanni Cannarozzo1
1Department of Systems Medicine, University of Rome, “Tor Vergata”, Italy
2Department of Health Sciences, University of Catanzaro “Magna Græcia”, Italy
3Unit of Dermatology, Complesso Integrato Columbus, Rome, Italy

Actinic keratoses (AK) are pre-neoplastic lesions related to an excessive ultraviolet exposure that represent an emerging issue in the area of skin diseases which undergo high risk for developing squamous cell carcinoma (SCC). In this open study, we tested the safety efficacy profile of sequential ablative laser and Ingenol Mebutate gel (IngMeb). Thirteen patients with a total of 99 lesions were selected for this open study. When multiple lesions on the same area were found, the treatment area was split in half. In one group, fractional CO2 laser microablative treatment was performed the day before three daily applications of IngMeb 150 lg/g; the other group received IngMeb without previous laser ablation. Fiftysix lesions were treated with laser and IngMeb and a total of 43 lesions in the second group were treated with IngMeb alone. Results at the 12-week follow-up visit showed that a clearance rate of 50/56 (89.2%) had been achieved. On the side that was not pre-treated with laser, 31 out of 43 lesions were cleared (72.1%). In our opinion, ablative fractional laser treatment could improve topical treatment of AKs, or provide a further therapeutic option for resistant patients.

actinic keratosis, Ingenol Mebutate, laser-assisted drug delivery, laser treatment

[pdfjs-viewer url=”http%3A%2F%2Fgild-ftp.com%2Fwp-content%2Fuploads%2F2017%2F03%2FEuropean_Journal_of_Inflammation-2016-Nisticoo-200-5.pdf” viewer_width=100% viewer_height=1360px fullscreen=true download=true print=true]